tbuckley/cabot-search huggingface dataset:
Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies
Authors: Francesca Zammarchi, David G. Williams, Lauren Adams, Karin Havenith, Simon Chivers, Francois D'Hooge, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
Journal: Blood (2015)
Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
Authors: T. E. Witzig, J. Vose, D. Pietronigro, K. Takeshita, A. Ervin-Haynes, J. Zeldis, P. H. Wiernik
Journal: Journal of Clinical Oncology (2007)

8066 Background: Lenalidomide, an immunomodulatory drug, is approved in the US for treatment of relapsed/refractory multiple myeloma and myelodysplastic syndromes associated with a deletion 5q[31] cytogenetic abnormality. Lenalidomide also has activity in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. This study was designed to assess the safety and efficacy of lenalidomide monotherapy in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Methods: Patients with relapsed/refractory indolent NHL with measurable disease after at least 1 prior treatment regimen were eligible. Patients received 25 mg lenalidomide orally once daily on Days 1–21 every 28 days and continued therapy for 52 weeks as tolerated or until disease progression. Response and progression were evaluated using the IWLRC methodology. Results: As of enrollment cut-off, 43 patients received drug and 27 were evaluable for response. The median age was 63 (43–82) and 12 were female. Histology was small lymphocytic lymphoma [SLL] (n=12), follicular center lymphoma grades 1,2 [FCL] (n=12) and nodal marginal B-cell lymphoma [NML] (n=3). Median time from diagnosis to lenalidomide was 4.3 (0.4- 24) years and median number of prior treatment regimens was 3 (1–17). Seven patients (26%) exhibited an objective response (2 complete responses (CR), 1 complete response unconfirmed (CRu) and 4 partial responses (PR)), 9 had stable disease (SD) for a tumor control rate (TCR) of 59% and 11 progressive disease (PD). Responses were produced in each of the indolent histologic subtypes studied: SLL (3/12), FCL (3/12) and NML (1/3). Since most responses develop at ≥ 4 months, additional responses may be seen in early SD patients with longer follow-up. Five patients (12%) exhibited Grade 4 neutropenia, and Grade 3 adverse events were neutropenia (16%) and thrombocytopenia (14%). Conclusion: Lenalidomide oral monotherapy is active with manageable side effects in relapsed/refractory indolent NHL. [Table: see text]
Skin Lesions in Malignancy
Authors: D. S. Madhumathi, Rao N. Raman, Devi V. Lakshmi, Devi M. Gayathri, Acharya S. Rani
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.7.2098 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11283144 Skin Lesions in Malignancy Case 1. Chronic Myeloid Leukemia in Lymphoid Blast Crisis Presenting as Multiple Cuteneous Masses D. S. MadhumathixD. S. MadhumathiSearch for articles by this author , Rao N. RamanxRao N. RamanSearch for articles by this author , Devi V. LakshmixDevi V. LakshmiSearch for articles by this author , Devi M. GayathrixDevi M. GayathriSearch for articles by this author , Acharya S. RanixAcharya S. RaniSearch for articles by this author Show More Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India, Copyright © 2001 American Society of Clinical Oncology https://doi.org/10.1200/JCO.2001.19.7.2098 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Gene Expression Profile Alone Is Inadequate In Predicting Complete Responses In Multiple Myeloma
Authors: Samir B. Amin, Stephane Minvielle, Bret Hanlon, Parantu K Shah, Cheng Li, Yi Li, David Swanson, Philippe Moreau, Florence Magrangeas, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2010)
Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma
Authors: Alessandra Romano, Antonella Chiechi, Calogero Vetro, Nunziatina Parrinello, Amy van Meter, Gregory Orloff, Dipti Patel, Alexander I. Spira, Francesco Di Raimondo, Lance Liotta, Virginia Espina
Journal: Blood (2010)
The Big Picture: Celebrating death
Authors: Richard Hurley
Journal: BMJ (2016)

MARCO UGARTE/AP/PA

As millions of people in the United Kingdom took part in Hallowe’en this week, so others worldwide have been remembering the dead.

Mexico’s Day of the Dead, for example, is not sombre and has traditionally entailed people dressing up as dead relatives to have a picnic at their graves, but now the day is being celebrated on a grander scale. Last Saturday …
Favorable Risk Group Acute Myeloid Leukemia in Children and Young Adult Treated in Uniform Protocol in Casablanca, Morocco. a Preliminary Analysis
Authors: Igala Marielle, Mouna Lamchaheb, Nisrine Khoubila, Siham Cherkaoui, Bouchra Oukache, Nazha Hda, Uma H. Athale, Asmaa AQ Quessar
Journal: Blood (2015)
Clinical Features and Outcome of 147 Patients with Diffuse Large B-Cell Lymphoma and Hepatitis C Virus Infection.
Authors: Carlo Visco, Luca Arcaini, Michele Merli, Annalisa Andreoli, Sara Burcheri, Achille Ambrosetti, Ercole Brusamolino, Mario Lazzarino, Giovanni Pizzolo, Francesco Rodeghiero
Journal: Blood (2005)
Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic Hypermutation
Authors: Lars Klemm, Cihangir Duy, Niklas Feldhahn, John Groffen, Yong-mi Kim, Wolf-Karsten Hofmann, Hassan Jumaa, Michael R Lieber, Rafael Casellas, Markus Muschen
Journal: Blood (2008)
NIMG-23A CONNECTOMIC PHENOTYPE OF 1p/19q LOSS OF HETEROZYGOSITY IN LOW-GRADE GLIOMA
Authors: Linda Douw, Julie Miller, Elizabeth Gerstner
Journal: Neuro-Oncology (2015)

The efficiency of a healthy brain network (the ‘connectome’) is positively related to physical and cognitive function. We sought to determine whether changes in network efficiency were related to loss of heterozygosity (LOH) at 1p/19q, a favorable prognostic marker in low-grade glioma (LGG). The presurgical diffusion tensor imaging (DTI) of LGG patients (WHO grade II) with known 1p/19q status treated at MGH were retrospectively analyzed. Processing included co-registration with anatomical 3D images, probabilistic tractography with FSL, and binary network construction based on the number of streamlines connecting each parcel from the Automated Anatomical Labeling atlas for which a benchmark healthy connectome (HC) is available. Path length (the average shortest number of steps between each network region) of the whole brain and the hemisphere contralateral to the tumor were compared to the HC by one-sample Wilcoxon signed rank tests. Path lengths of patients with and without LOH were compared using Mann-Whitney U tests. Thirteen patients with images acquired between 2008-2014 were included (8 male, mean age 42 ± 14 years, 8 left-sided tumors, median KPS 90). Four patients showed LOH. At the group level, patients had longer whole-brain path length (2.5 ± 0.3 steps, p = 0.023) and contralateral path length (2.0 ± 0.2 steps, p = 0.033) than the HC (2.3 and 1.9 steps, resp.), indicating a less efficient connectome. Patients with LOH had shorter contralateral path length than those without (2.5 ± 0.3 versus 2.3 ± 0.1 steps, p = 0.011). Age, gender, presurgical tumor volume, and performance status did not influence these results significantly. These results indicate that patients with LGG have decreased connectome efficiency even in the contralateral hemisphere, highlighting the global impact of local tumors. 1p/19q LOH is associated with a more efficient connectome, supporting the more favorable performance status and prognosis in these patients. Connectivity is therefore a promising noninvasive biomarker for prognosis and holds potential for treatment monitoring.
Vaccination with ΔCD40L or Flagellin Gene-Modified T Cells Activates Dendritic Cells In Vivo and Induces a Potent Anti-Tumor Immune Response
Authors: Adham S Bear, Meghan M Turnis, Xiao-Tong Song, Russell Cruz, An Lu, Stephen Gottschalk, Cliona M Rooney, Aaron E Foster
Journal: Blood (2011)
ADDUCTOR SQUEEZE TESTING IN SOCCER: PRECISION, TORQUE PRODUCTION &amp; IMPLICATIONS FOR SCREENING
Authors: N Light, K Thorborg
Journal: British Journal of Sports Medicine (2016)

Reduced adductor strength is a known risk factor for groin injury amongst footballers. Team clinicians often test the adductor strength of players using isometric squeeze tests, performed regularly during the season to monitor fluctuations in scores. Various positions of testing are commonly used but it is not clear on which are the most reliable, stressful and ultimately capable of detecting subtle deficits in strength. In this study, three common adductor squeeze tests (long-lever, short lever in adduction and short lever-in abduction/external rotation) were investigated for differences in reliability and torque production. Using a test-retest reliability and cross-sectional comparison design, twenty professional footballers (16–33 years) without previous or current groin pain, performed a series of isometric squeeze tests measured by hand-held dynamometry. The tests were performed on two test days separated by two weeks, with both relative and absolute reliability determined, alongside torque production. Results showed no systematic variation for any of the tests, when the mean of three measures was used (ICC=0.84–0.97, MDC%=6.6–19.5). However, the least variation was observed using the long-lever position (ICC=0.97, MDC%=6.6), which also generated higher mean torque values when compared with short-lever in adduction (69%) and short lever in abduction/external rotation (11%) positions (p&lt;0.001). In conclusion, all three tests described in this study are reliable methods of measuring adductor squeeze strength. However, long-lever squeeze testing displayed the highest adductor torque production and test-retest precision. Both of these test attributes are arguably vital for squeeze test monitoring, in order to confidently detect clinically meaningful deficits in scores that may predispose a player to subsequent injury.
Unusual Hematologic Malignancies
Authors: Ulka Vaishampayan, Maria E. Dan
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.17.3739 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12202675 Unusual Hematologic Malignancies Case 2. Mediastinal Germ Cell Tumor, Malignant Histiocytosis, and Acute Leukemia Ulka VaishampayanxUlka VaishampayanSearch for articles by this author , Maria E. DanxMaria E. DanSearch for articles by this author Show More Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI https://doi.org/10.1200/JCO.2002.20.17.3739 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Rpl13a small nucleolar RNAs regulate systemic glucose metabolism
Authors: Jiyeon Lee, Alexis N. Harris, Christopher L. Holley, Jana Mahadevan, Kelly D. Pyles, Zeno Lavagnino, David E. Scherrer, Hideji Fujiwara, Rohini Sidhu, Jessie Zhang, Stanley Ching-Cheng Huang, David W. Piston, Maria S. Remedi, Fumihiko Urano, Daniel S. Ory, Jean E. Schaffer
Journal: Journal of Clinical Investigation (2016)

Small nucleolar RNAs (snoRNAs) are non-coding RNAs that form ribonucleoproteins to guide covalent modifications of ribosomal and small nuclear RNAs in the nucleus. Recent studies have also uncovered additional non-canonical roles for snoRNAs. However, the physiological contributions of these small RNAs are largely unknown. Here, we selectively deleted four snoRNAs encoded within the introns of the ribosomal protein L13a (Rpl13a) locus in a mouse model. Loss of Rpl13a snoRNAs altered mitochondrial metabolism and lowered reactive oxygen species tone, leading to increased glucose-stimulated insulin secretion from pancreatic islets and enhanced systemic glucose tolerance. Islets from mice lacking Rpl13a snoRNAs demonstrated blunted oxidative stress responses. Furthermore, these mice were protected against diabetogenic stimuli that cause oxidative stress damage to islets. Our study illuminates a previously unrecognized role for snoRNAs in metabolic regulation.
Targeting Late Relapsed Acute Myeloid Leukemia Cells by Cytotoxic T Cells Generated from Late but Not Early Leukemic Antigen-Presenting Dendritic Cells.
Authors: Yin Liang, Lily Lien, Shuhong Han, Chun-Rong Tong, Zhi-Yong Gao, Tong Wu, Jih-Luh Tang, Dao-Pei Lu, Lung-Ji Chang
Journal: Blood (2007)
Health consequences of shift work and insufficient sleep
Authors: Göran Kecklund, John Axelsson
Journal: BMJ (2016)

This review summarises the literature on shift work and its relation to insufficient sleep, chronic diseases, and accidents. It is based on 38 meta-analyses and 24 systematic reviews, with additional narrative reviews and articles used for outlining possible mechanisms by which shift work may cause accidents and adverse health. Evidence shows that the effect of shift work on sleep mainly concerns acute sleep loss in connection with night shifts and early morning shifts. A link also exists between shift work and accidents, type 2 diabetes (relative risk range 1.09-1.40), weight gain, coronary heart disease (relative risk 1.23), stroke (relative risk 1.05), and cancer (relative risk range 1.01-1.32), although the original studies showed mixed results. The relations of shift work to cardiometabolic diseases and accidents mimic those with insufficient sleep. Laboratory studies indicate that cardiometabolic stress and cognitive impairments are increased by shift work, as well as by sleep loss. Given that the health and safety consequences of shift work and insufficient sleep are very similar, they are likely to share common mechanisms. However, additional research is needed to determine whether insufficient sleep is a causal pathway for the adverse health effects associated with shift work.
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Authors: Bing Cui, Emanuela M. Ghia, Liguang Chen, Laura Z. Rassenti, Christopher DeBoever, George F. Widhopf, Jian Yu, Donna S. Neuberg, William G. Wierda, Kanti R. Rai, Neil E. Kay, Jennifer R. Brown, Jeffrey A. Jones, John G. Gribben, Kelly A. Frazer, Thomas J. Kipps
Journal: Blood (2016)
Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2rγnull Mice Engrafted with Mobilized Human Hematopoietic Stem Cells.
Authors: Leonard Shultz, Bonnie L. Lyons, Lisa M. Burzenski, Bruce Gott, X. Chen, Stanley Chaleff, Malak Kotb, Stephen D. Gillies, Dale L. Greiner, Rupert Handgretinger
Journal: Blood (2004)
Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility
Authors: Jonathan Benjamin, Ginna G Laport, Keri Tate, Leah Galvez, Randall Armstrong, Kevin Sheehan, Sally Arai, Robert Lowsky, Laura Johnston, David B. Miklos, Judith Shizuru, Wen-Kai Weng, Robert Negrin
Journal: Blood (2013)
K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).
Authors: B. Douglas Smith, Yvette L. Kasamon, Carole B. Miller, Christina Chia, Kathleen Murphy, Jeanne Kowalski, Irena Tartakovsky, Barbara Biedrzycki, Richard J. Jones, Kristen Hege, Hyam I. Levitsky
Journal: Blood (2005)
Uncommon Syndromes and Treatment Manifestations of Malignancy
Authors: G. Rossi, M. Lucioni, L. Sammarchi, M. Paulli, G. Beluffi, A. Martini, A. Ravelli
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.21.1.166 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12506186 Uncommon Syndromes and Treatment Manifestations of Malignancy Case 1. Unusual Association of Lupus and Sarcoma G. RossixG. RossiSearch for articles by this author , M. LucionixM. LucioniSearch for articles by this author , L. SammarchixL. SammarchiSearch for articles by this author , M. PaullixM. PaulliSearch for articles by this author , G. BeluffixG. BeluffiSearch for articles by this author , A. MartinixA. MartiniSearch for articles by this author , A. RavellixA. RavelliSearch for articles by this author Show More Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Università di Pavia, Pavia; and Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Università di Genova, Genova, Italy https://doi.org/10.1200/JCO.2003.21.1.166 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Combined Effects of <i>in Utero</i> and Adolescent Tobacco Smoke Exposure on Lung Function in C57Bl/6J Mice
Authors: David Drummond, Mélissa Baravalle-Einaudi, Guillaume Lezmi, Shamila Vibhushan, Marie-Laure Franco-Montoya, Alice Hadchouel, Jorge Boczkowski, Christophe Delacourt
Journal: Environmental Health Perspectives (2016)

Fetal determinants of airway function, such as
Evaluation of α-1-acid glycoprotein as a prognostic factor of survival in patients with stage II-III esophageal carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil chemotherapy followed by surgery.
Authors: Yusuke Sasaki, Ken Kato, Koh Furuta, Naoki Takahashi, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Natsuko T. Okita, Atsuo Takashima, Tetsuya Hamaguchi, Yasuhide Yamada, Narikazu Boku
Journal: Journal of Clinical Oncology (2015)

100 Background: Serum α-1-acid glycoprotein (AAG) level was an independent predictor of response and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel chemotherapy. However, it has not been determined whether AAG is associated with the outcomes of esophageal cancer patients who have been treated with a combination of docetaxel, cisplatin and 5-fluorouracil (DCF) as neoadjuvant therapy. Methods: This retrospective study included a cohort of 39 patients with clinical stage II/III esophageal cancer, based on the International Union Against Cancer TNM classification system 7th edition, who were treated with neoadjuvant DCF followed by surgery. DCF consisted of docetaxel (70mg/m 2 ) and cisplatin (70mg/m 2 ) on day 1, and continuous infusion of 5-fluorouracil (750mg/m 2 /day) on days 1-5, with this regimen repeated every 3 weeks up to three cycles. Patients were divided into groups by median value of baseline AAG levels. Patient characteristics, preoperative clinical stage, chemotherapy effect, and survival were compared between the high and low AAG groups. Results: The clinical stage IIA, IIB, IIIA, IIIB and IIIC were 4, 4, 14, 17 and 0, respectively. The completion rate of three cycles of chemotherapy was 76.9% (30/39). All patients underwent surgery and the R0 resection rate was 97.4% (38/39). The best overall response rate of DCF was 48.7% with a pathological complete response of 5.1%. The 2-year progression-free survival and overall survival (OS) rates were 60.5% and 76.9%, respectively. The median serum AAG was 95 g/L, ranging from 57 to 228 g/L. A trend of lower response rate (35.0% vs. 57.9%; P = 0.20) and shorter OS (median not reached; hazard ratio [HR] 2.08; P = 0.24) was observed in patients with a high AAG level (AAG &gt; 95 g/L) compared with a low AAG level (AAG ≦ 95 g/L). Multivariate analysis showed an AAG level hazard ratio of 1.60 (P = 0.59) for OS. Conclusions: There was a trend toward improved response and survival with low serum AAG level, for patients with esophageal cancer who received neoadjuvant DCF chemotherapy.
Response to Ifosfamide and Mesna
Authors: Karen H. Antman, Louise Ryan, Anthony Elias, Debra Sherman, Holcombe E. Grier
Journal: Journal of Clinical Oncology (1989)

An error was made in the response rates in the report "Response to Ifosfamide and Mesna: 124 Previously Treated Patients With Metastatic or Unresectable Sarcoma" by Antman et al, published in the January 1989 issue (J Clin Oncol 7:126–131, 1989). The report should read: Abstract and Response section: "... 22 (patients) (18%) had a complete or partial response (95% exact confidence interval, 11% to 26%)"; Table 1: response rate, 18%, and for those fully eligible and evaluable, 20%; and Response section: "The response rate for the subset of 110 fully eligible and available patients was 20% (exact confidence interval, 13% to 29%)."
Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer
Authors: Albert J. Farias, Xianglin L. Du
Journal: Journal of Clinical Oncology (2017)

Purpose Previous studies suggest that adherence to adjuvant endocrine therapy (AET) for patients with breast cancer is suboptimal, especially among minorities, and is associated with out-of-pocket medication costs. This study aimed to determine whether there are racial/ethnic differences in 1-year adherence to AET and whether out-of-pocket costs explain the racial/ethnic disparities in adherence. Methods This retrospective cohort study used the SEER-Medicare linked database to identify patients ≥ 65 years of age with hormone receptor-positive breast cancer who were enrolled in Medicare Part D from 2007 to 2009. The cohort included non-Hispanic whites, blacks, Hispanics, and Asians. Out-of-pocket costs for AET medications were standardized for a 30-day supply. Adherence to tamoxifen, aromatase inhibitors (AIs), and overall AET (tamoxifen or AIs) was assessed using the medication possession ratio (≥ 80%) during the 12-month period. Results Of 8,688 patients, 3,197 (36.8%) were nonadherent to AET. Out-of-pocket costs for AET medication were associated with lower adjusted odds of adherence for all four cost categories compared with the lowest category of ≤ $2.65 ( P < .01). In the univariable analysis, Hispanics had higher odds of adherence to any AET at initiation (OR, 1.30; 95% CI, 1.07 to 1.57), and blacks had higher odds of adherence to AIs at initiation (OR, 1.27; 95% CI, 1.04 to 1.54) compared with non-Hispanic whites. After adjusting for copayments, poverty status, and comorbidities, the association was no longer significant for Hispanics (OR, 0.95; 95% CI, 0.78 to 1.17) or blacks (OR, 0.96; 95% CI, 0.77 to 1.19). Blacks had significantly lower adjusted odds of adherence than non-Hispanic whites when they initiated AET therapy with tamoxifen (OR, 0.54; 95% CI, 0.31 to 0.93) after adjusting for socioeconomic, clinic, and prognostic factors. Conclusion Racial/ethnic disparities in AET adherence were largely explained by women's differences in socioeconomic status and out-of-pocket medication costs.